Sorafenib in advanced clear-cell renal-cell carcinoma - Wikidata - awgldk - TriplyDB

Sorafenib in advanced clear-cell renal-cell carcinoma

Sorafenib in advanced clear-cell renal-cell carcinoma

http://www.wikidata.org/entity/Q28282767

about

Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets Combining the receptor tyrosine kinase inhibitor AEE788 and the mammalian target of rapamycin (mTOR) inhibitor RAD001 strongly inhibits adhesion and growth of renal cell carcinoma cells Development of coronary artery stenosis in a patient with metastatic renal cell carcinoma treated with sorafenib Vascular endothelial growth factor inhibitors: investigational therapies for the treatment of psoriasis Targeted therapy for advanced renal cell carcinoma Protein-tyrosine phosphatase 4A3 (PTP4A3) promotes vascular endothelial growth factor signaling and enables endothelial cell motility.SPOP promotes tumorigenesis by acting as a key regulatory hub in kidney cancer Pericytes promote endothelial cell survival through induction of autocrine VEGF-A signaling and Bcl-w expression A comprehensive overview of targeted therapy in metastatic renal cell carcinoma mTOR inhibitors in advanced renal cell carcinoma Axitinib for the management of metastatic renal cell carcinoma State of the science: an update on renal cell carcinoma Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment New advances in targeted gastric cancer treatment Immunobiology and immunotherapy in genitourinary malignancies Contemporary Treatment of Metastatic Renal Cell Carcinoma Review of renal cell carcinoma and its common subtypes in radiology Modulation of Autophagy by Sorafenib: Effects on Treatment Response Axitinib in the treatment of renal cell carcinoma: patient selection and perspectives Targeting the Sonic Hedgehog Signaling Pathway: Review of Smoothened and GLI Inhibitors Beyond evidence-based data: scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinoma Vascular Complications of Cancer Chemotherapy Chinese guidelines on the management of renal cell carcinoma (2015 edition)Sequence of treatment in locally advanced and metastatic renal cell carcinoma Cytoreductive surgery in the era of targeted molecular therapy Profile of nintedanib in the treatment of solid tumors: the evidence to date MEK and PI3K inhibition in solid tumors: rationale and evidence to date Targeting PD-1/PD-L1 in the treatment of metastatic renal cell carcinoma The Emerging Regulation of VEGFR-2 in Triple-Negative Breast Cancer Targeting RTK Signaling Pathways in Cancer More than a Decade of Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors: What We Have Learned and What the Future Holds Clinical experience with everolimus in the second-line treatment of advanced renal cell carcinoma Cytoreductive nephrectomy and its role in the present-day period of targeted therapy.Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs: systematic review and meta-analyses Renal cell carcinoma: histological classification and correlation with imaging findings Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: a systematic review and meta-analysis of clinical trials Profile of tivozanib and its potential for the treatment of advanced renal cell carcinoma Cardiac toxicity in cancer survivors Role of immunotherapy for renal cell cancer in 2011 Inhibition of the methionine aminopeptidase 2 enzyme for the treatment of obesity

P2860

Q21183974-F6E2708A-1C28-4BDB-8ED4-440108B266F2 Q21260390-44A932B2-6FC0-4277-9B33-C5CB9CFFC085 Q21261282-3022F70F-DB09-49A5-BC4A-843A86EC06D5 Q22305863-A7BB4BEB-DDEB-4210-A5B3-421E6A16C5E2 Q24242946-43DF7FD9-53AC-4A7E-82D6-82D9FDD008AF Q24318418-CCB8014F-3B76-4746-BA68-4D979C696541 Q24339492-E016B011-150C-4BCB-BAFF-8DEF54432482 Q24595357-CF90DC86-E56E-4DF5-A446-D79E07C386D8 Q24606852-D1B17430-8DCD-4264-8B21-94A453DEEAA3 Q24612127-82269D7C-AE71-41C8-A5C6-C53DD62C94DF Q24613720-DCA16405-98FC-4B61-9888-74A752647140 Q24630685-C7CA6EE2-5DDD-46B1-B4AB-98B472ADF0FA Q24657761-F3A31A25-D5A7-4B2B-8708-4918E046EC3A Q26738548-B1F42038-B3CE-4BF8-8B60-02541F526883 Q26738668-2F673DEA-9E91-463E-9C86-A0474AE92D0A Q26740594-8F1A3EE9-1B14-413F-B523-0D06D76162DE Q26744297-9284E5E9-3679-497F-8E2F-B67090D385AF Q26745320-00BA3769-6D45-4CC0-88E1-35FC440232FC Q26751341-99002CF9-FDD6-413A-9B12-E22F47C6B4E7 Q26764892-145045B0-61B8-4293-8DA6-817C222B5C27 Q26766240-3796FD6C-6EA4-4E33-AE2B-1CE616DED6D2 Q26766269-4803136E-596B-471D-8CE7-2523BAF7E41A Q26772206-521A4DAF-AAD3-4187-B197-801316CAE97D Q26773653-C85BD2C3-AB2D-4F13-A4CB-6C85B5AE34BE Q26774134-E5F29FE5-FA77-4D6E-8E63-2FDFD6EB74A8 Q26775134-183C1421-A743-4E16-B985-A3473F70DE7F Q26775573-EA8D3541-AA1C-4E65-9540-25258E1F673A Q26775769-4DB7E286-0FC9-4E98-8DA7-87D9EE5FC984 Q26779248-DCC2727D-9E81-4183-8114-F1C3731173B8 Q26781278-D48F9733-0701-493E-A0C1-E3A067356A3A Q26781662-8F425D9D-AB80-4DC4-BD7F-22034E9F7C16 Q26783514-EDF5A911-3867-475E-8A38-F5A12FBCF570 Q26783520-9E7368B6-67E4-47FD-8D55-3036F7E0BAD1 Q26786243-328A5FA9-F7A8-4ACE-93B9-56DDE288D01E Q26799781-C3724438-FCFA-45C1-94F3-FBD71583A05F Q26822790-5CF2E728-672E-45F6-9D54-1976C3F07430 Q26827319-9A96B4E0-81C8-4F5B-9876-0C46DB23462D Q26851957-A2864655-9BAF-4BF9-BA30-639DE09102E6 Q26853453-A08A1A21-8621-4E2C-B8F8-432D7D360995 Q26859210-276EFDE6-0D43-4507-A389-ED3E6BEAD261

P2860

Sorafenib in advanced clear-cell renal-cell carcinoma

http://www.wikidata.org/entity/Q28282767

description

2007 nî lūn-bûn

@nan

2007 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Sorafenib in advanced clear-cell renal-cell carcinoma

@ast

Sorafenib in advanced clear-cell renal-cell carcinoma

@en

Sorafenib in advanced clear-cell renal-cell carcinoma

@nl

type

label

Sorafenib in advanced clear-cell renal-cell carcinoma

@ast

Sorafenib in advanced clear-cell renal-cell carcinoma

@en

Sorafenib in advanced clear-cell renal-cell carcinoma

@nl

prefLabel

Sorafenib in advanced clear-cell renal-cell carcinoma

@ast

Sorafenib in advanced clear-cell renal-cell carcinoma

@en

Sorafenib in advanced clear-cell renal-cell carcinoma

@nl

P1433

Q28282767-AF659E4B-504B-4685-83D4-9F3DB16C4038

P1476

Q28282767-A29FF170-8CCD-45F7-AE2B-E008330A378F

P2093

Q28282767-0BBE0219-06E6-4836-AF58-78018976178D

Q28282767-163DE3BD-BD62-4EBB-AC23-9E903CA6903E

Q28282767-25C6FF13-3B98-41EC-BB09-1CF772CAD85A

Q28282767-27949E26-CFBF-4A3C-A81D-3CA25630C304

Q28282767-31D7338F-B661-4100-9024-12192205CBE5

Q28282767-33E5FA10-E845-4EA2-8DC8-FE8EC537FD61

Q28282767-44559BD1-0333-481C-9D58-E76FA7C5329E

Q28282767-6E539108-A6D0-40A7-A569-9A6277AFA64B

Q28282767-78022DFD-AA41-4DE6-B9B9-D51A3C0726C6

Q28282767-7FE19EE8-C2D2-463A-AE9F-A97D9EF8EA50

P304

Q28282767-94E60DCB-32AE-4F5B-BCD5-F2E7BCDFF5A9

P31

Q28282767-A3BEF637-E697-4A63-8A3E-348E46563A7F

P3181

Q28282767-91CDC1A4-553F-44C0-A9FB-1D7BC5121823

P356

Q28282767-1B1EAC27-1502-467C-9660-9439DA59D413

P407

Q28282767-E908761C-C17F-4F91-94F8-446B6AC4FFE2

P433

Q28282767-8A336EDF-585F-4000-AA3E-B6AAC515D919

P478

Q28282767-C9A808ED-414D-4CCC-BA44-81D4F6683EAE

P50

Q28282767-2576FC46-36B8-4ADB-BF67-4C6F9F1BBFAB

Q28282767-9D1D7B29-90D4-4AF7-A376-043FA1D54EEB

Q28282767-BE8B3381-5044-494A-8B55-F09FCC47F5A9

P577

Q28282767-3AA2C023-01CB-494B-AD03-BFCDF871EEC8

P698

Q28282767-16C5CC8E-6B2F-4042-ADB6-BAF39F29CE38

P3181

P356

P1433

The New England Journal of Medicine

P1476

Sorafenib in advanced clear-cell renal-cell carcinoma

@en

P2093

Apurva A Desai

http://www.w3.org/2001/XMLSchema#string

Bernard Escudier

http://www.w3.org/2001/XMLSchema#string

Cezary Szczylik

http://www.w3.org/2001/XMLSchema#string

Christine Chevreau

http://www.w3.org/2001/XMLSchema#string

Ewa Solska

http://www.w3.org/2001/XMLSchema#string

Martin Gore

http://www.w3.org/2001/XMLSchema#string

Michael Siebels

http://www.w3.org/2001/XMLSchema#string

Minghua Shan

http://www.w3.org/2001/XMLSchema#string

Ronald M Bukowski

http://www.w3.org/2001/XMLSchema#string

Scott Freeman

http://www.w3.org/2001/XMLSchema#string

P304

125-134

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

19154

http://www.w3.org/2001/XMLSchema#string

P356

10.1056/NEJMOA060655

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

356

http://www.w3.org/2001/XMLSchema#string

P50

Frederic Rolland

P577

2007-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17215530

http://www.w3.org/2001/XMLSchema#string